Palliative care of dyspnea at the end of life;Traitement de la dyspnée en fin de vie

Revue des Maladies Respiratoires

Volumn 21, Issue 3 I, 2004, Pages 465-472

  Marin, I ^a  

^a DELAFONTAINE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; DYSPNEA; EDITORIAL; HUMAN; HYPERCAPNIA; OXYGEN THERAPY; PALLIATIVE THERAPY; TERMINAL CARE;

EID: 3242742073     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(04)71349-2     Document Type: Editorial

References (62)

1. Mazzocato C, Steiner N: Contrôle des symptômes en soins palliatifs: la dyspnée terminale. Med Hyg 1992; 50: 164-7.
2. Twicross RG: A lack respiratory symptoms in therapeutics in terminal cancer. Londres, Churchill Livngston 1984.
3. Official statement of the American Thoracic Society: dyspnea. Am J Respir Crit Care Med 1999; 159: 321-40.
4. Altose MD: Assessment and management of breathlessness. Chest 1985; 88: 77-83.
5. Tison A: L'encombrement des voies respiratoires en fin de vie: analyse bibliographique. Thèse pour le doctorat en médecine, Université de Nantes, 2002.
6. Bedard J, Dionne A, Dionne L: Expérience de la maison Michel Sarrazin. Analyse dyu profil de 952 patients cancéreux en phase terminale. J Palliative Care 1991; 7: 42-57.
7. Michard P, Marin I, Camberlein Y, Abiven M: Soins palliatifs des maladies en phase terminale, expérience de l'unité de soins palliatifs de l'Hôpital International de l'université de Paris. Ann Med Int 1990; 141: 313-8.
8. Michard P: La dypsnée en soins palliatifs. Mémoire d'oncologie, Paris, 1989.
9. Heyse-Moore L, Ross V, Mulles MA: How much of a problem is dyspnoea in advanced cancer? Palliative Med 1991; 5: 20-6.
10. Higginson I, MacCarthy M: Measuring Symptoms in terminal cancer: are pain and dyspnoea controlled? J Royal Soc Med 1989; 82: 264-7.
11. Gore JM, Brophy CJ, Greenstone MA: How well care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 5: 1000-6.
12. Chavannes N: Une approche palliative de la BPCO et de l'insuffisance cardiaque grave. J Europ de soins palliatifs 2001; 8: 225-7.
13. Lichter I, Hunt E: The last 48 Hours of life. J Palliative Care 1990; 6: 7-15.
14. Muers MF, Round CE: Palliation of symptoms in non-small cell lung cancer: a study the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993; 48: 339-43.
15. Dudgeon DJ, Lertzman M: Dyspnoea in the advanced Cancer Patient. J Pain Symptom Manag 1998; 16: 212-9.
16. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement C: Dypnea in cancer patients: prevalence and associated factors. J Pain Symptom Manag 2001; 21: 95-102.
17. D Reuben B, Mor V: Dypnea in terminally ill cancer patients. Chest 1989; 2: 234-6.
18. Dudgeon DJ, Lertzman M, Askew GR: Physiological changes and clinical correlations of dyspnoea in cancer out patients. J Pain Symptom Manag 2001; 21: 373-9.
19. Marin I, Andrieu JM, Chrétien J: Cancers bronchopulmonaires: approche médicale des dernières semaines de vie: étude de 191 patients. Ann Med Int 1987; 138: 90-5.
20. Vogt P: Physiopathologie cardiaque de la dyspnée. Med Hyg 1994; 52: 2253-6.
21. Chevrolet JC: Physiopathologie de la dyspnée. Med Hyg 1994; 52: 2245-52.
22. Manning H, Schwartzstein RM: Pathophysiology of dyspnea. N Eng J Med 1995; 333: 1547-53.
23. Camberlein Y, Natali F: Dyspnée et soins palliatifs. Mémoire sous commission SOFRED 1992.
24. Brechot JM: Complications respiratoires du traitement du cancer bronchique. Med Hyg 2000; 58: 783-5.
25. Noseda A, Yernault JC: Évaluation de la dyspnée. Med Hyg 1996; 54: 775-7.
26. Killian KJ: The objective measurement of breathlessness. Chest 1985; 88: 84-9.
27. Altose MD: Psychophysics an approach to the study of respiratory sensation and the assessment of dyspnea. Am Rev Respir Dis 1987; 135: 1227-8.
28. Demediuk BH, Manning H, Lilly J, Fencl V, Weinberger S, Weiss J, Schwartzstein RM: Dissociation between dyspnea and respiratory effort. Am Rev Respir Dis 1992; 146: 1222-5.
29. Jeffery Mador M, Kufel TJ: Reproductibility of visual analog scale measurements of dyspnoea in patients with chronic obstructive pulmonary disease. Am Rev Respir Med 1992; 146: 82-7.
30. Schiffman GL, Stansbury DW, Fischer CE, Sato RI, Light, Brown SE: Indomethacin and perception of dyspnea in chronic airflow obstruction. Am Rev Respir Dis 1988; 137: 1094-8.
31. O'Neill PA, Stark RD, Morton PB: Do prostaglandins have a role in breathlessness? Am Rev Respir Dis 1985; 132: 22-4.
32. Coleridge JC, Colerige HM: Afferent fibres and cardiorespiratory reflexes. Am Rev Respir Dis 1977; 115: 251-60.
33. Nishino T, Ide T, Sudo T, Sato J: Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161: 1963-7.
34. Ong KC, Korc AC, Chong WF, Earnest A, Wang YT. Effects of inhaled furosemide on exertional dyspnea in chronic obsructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1028-33.
35. Woodcock A, Gross ER, Geddes DM: Drug treatment of breathlessness: contrasing effects of diazepam and promethazine in pink puffers. Br Med J 1981; 283: 343-6.
36. Butland RJ, Woodcock A: Endogenous opioids (endorphins) and the control of breathing. N Eng J Med 1981; 305: 1096.
37. Bellofiore S, Di Maria GU, Pritivera S, Sapeinza S, Milic-Emili J, Mistretta A: Endogenous oppioids modulate the increase in ventilatory output and dyspnea during senere acute broncho constriction. Am Rev Respir Dis 1990; 142: 812-6.
38. Woodcock A, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM: Effects of dihydrocodéine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease. N Eng J Med 1981; 305: 1611-6.
39. Supinski G, Dimarco A, Bark, Chapman K, Clary S, Altose M: Effect of codeine on the sensations elicited by loaded breathing. Am Rev Respir Dis 1990; 141: 1516-21.
40. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadlez KE: A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-44.
41. Beaufort W, Saylor T, Stansbury DW, Avalos K, Light RW: Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patients. Chest 1993; 104: 175-8.
42. Bruera E, Macmillan K, Pither J, MacDonald RN: Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manag 1990; 5: 341-4.
43. Allard P, Lamontagne C, Bernard P, Tremblay C: How effective are supplementary dose of opioids for dyspnoea in terminally cancer patients? A randomised continuous sequential clinical trial. J Pain Symptom Manag 1999; 17: 256-65.
44. Cohen MH, Anderson, Krasnow RS, Spagnolo SV, Citron ML, Payne M, Fossiek BE: Continuous intravenous infusion of morphine for severe dyspnea. Southern Med J 1991; 84: 229-34.
45. Bruera E, MacEachern T, Ripamonti C, Hanson J: Subcutaneous morphine for dyspnea in cancer patients. Ann Int Med 1993; 119: 906-7.
46. Fitting JW: Traitement palliatif de la dyspnée. Med Hyg 1994; 52: 2261-4.
47. De Conno F, Spoldfi E, Caracen A, Ventafridda V: Does pharmalogical treatment affect the sensation of breathlessness in terminal cancer patients? Med Pall 1991; 5: 237-43.
48. Cowcher K, Hanks GW: Long-Term Management of respiratory symptoms in advanced cancer. J Pain Symptom Manag 1990; 5: 320-30.
49. Muers MF: Opiodis for dyspnoea. Thorax 2002; 57: 922-3.
50. Recommandations de bonne pratique soins palliatifs spé cificité d'utilisation des médicaments courants hors antalgiques. ANAES, octobre 2002.
51. Bruera E, De Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J: Effects of oxygen on dyspnoea in hypoxaemic termina-cancer patients. Lancet 1993; 342: 13-4.
52. Liss HP, Grant B: The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137: 1285-8.
53. Morel V, Brinchault G, Richard MS, Cheruel S, Delaval P: L'oxygénothérapie : une prescription singulière chez les malades en fin de vie. Réflexion d'une équipe soignante d'un service de pneumologie. Med Pall 2004; 3: 34-9.
54. Hacpille L: Dyspnée et soins palliatifs, Ed Cooper, Paris, Intermed. mai 2000.
55. Lassaunière JM, D'Hérouville D, Richard MS: Conduite à tenir devant une dyspnée terminale. Infokara 1992; 27: 29-33.
56. Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A'Hern R: Multicentre randomised controlled trial of nursing intervention for breahlessness in patients with lung cancer. BMJ 1999; 318: 901-4.
57. Starck RD, O Neil PA, Russell NJW, Heapy CG, Stretton TB: Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin Sci 1985; 69: 29-36.
58. Man GCW, Hsu K, Sproule BJ: Effect of alprazolam on exercise and dyspnoea in patient with chronic obstructive pulmonary disease. Chest 1986; 90: 832-6.
59. Young IH, Daviskas E, Keena: Effect of low doses nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989; 44: 387-90.
60. Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE: Effect of oral morphine in breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 126-33.
61. Eiser N, Denman WT, West C, Luce P: Oral diamorphine: lack of effect on dyspnoea and exercices tolerance in the « pink puffers » syndrome. Eur Respir J 1991; 4: 926-31.
62. Santiago TV, Remolina C, Scoles V, Edelman NH: Endorphins ant the control of breathing. Ability of naloxone restores flow-resistive load compensation in chronic obstructive pulmonary disease. N Eng J Med 1981; 304: 1190-5.